



**Fig. 1.** Effect of non-insulin-dependent diabetes on caffeine-induced  $\text{Ca}^{2+}$  release from the sarcoplasmic reticulum of adult cardiomyocytes. Cardiomyocytes were prepared and then loaded with fura 2 using the method described by Allo et al. [3]. Caffeine (10 mmol/l) was added at time 0 and changes in fluorescence measured over time for cells from control (▲) and non-insulin-dependent diabetic (●) hearts. The data are expressed as the difference in relative fluorescence (F) at 502 nm between cells exposed to caffeine and those incubated in the standard buffer used by Allo et al. [3]. Each point represents the mean  $\pm$  SEM of experiments carried out on three different cell preparations. \*  $p < 0.05$  vs non-diabetic control cells

ment in glucose utilization is largely linked to a defect in glucose transport [2].

We agree with the statement by Thompson and Mikhailidis that variables other than hyperglycaemia must be considered when investigating complications of diabetes. We have previously reported that one of the major defects of the non-insulin-dependent diabetic heart is an impairment in  $\text{Na}^+$ ,  $\text{Ca}^{2+}$  exchange, which contributes to an elevation in cytoplasmic calcium levels [3]. Moreover, recent studies with isolated myocytes displayed in Figure 1 show that calcium released from sarcoplasmic reticular stores by 10 mmol/l caffeine is elevated in non-insulin-dependent diabetes, demonstrating that cytoplasmic calcium levels, as well as intracellular calcium stores, are significantly elevated in the non-insulin-dependent diabetic heart. We believe that this elevation in intracellular calcium causes a reduction in diastolic compliance, triggering abnormalities in ventricular filling and cardiac performance [4].

Yours sincerely,  
S. Allo, M. Mozaffari, G. Wilson and S. W. Schaffer

## References

- Randle PJ, Garland PB, Hales CN, Newsholme EA, Denton RM, Pogson CI (1966) Interactions of metabolism and the physiological role of insulin. *Rec Prog Hormone Res* 22: 1–44
- Schaffer SW, Seyed-Mozaffari M, Cutcliff CR, Wilson GL (1986) Postreceptor myocardial metabolic defect in a rat model of non-insulin-dependent diabetes mellitus. *Diabetes* 35: 593–597
- Allo SN, Lincoln TM, Wilson GL, Green FJ, Watanabe AM, Schaffer SW (1991) Non-insulin-dependent diabetes-induced defects in cardiac cellular calcium regulation. *Am J Physiol* 260: C1165–C1171
- Schaffer SW, Mozaffari MS, Artman MF, Wilson GL (1989) Basis for myocardial mechanical defects associated with non-insulin-dependent diabetes. *Am J Physiol* 256: E25–E30

Dr. S. Schaffer  
Department of Pharmacology  
College of Medicine  
University of South Alabama  
MSB 3130  
Mobile, AL 36688-0002  
USA

## Plasma lipoprotein (a) concentration in diabetes mellitus

Dear Sir,

In a recent article, Császár and co-workers [1] reported no differences in lipoprotein (a) concentration in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients when compared to two Caucasian populations (Austrians and Hungarians). They concluded that the Lp(a) was not a risk factor contributing to atherosclerotic complications in diabetes.

We have studied a diabetic population and obtained different results some of which do not agree with their conclusions. Forty-four patients diagnosed with Type 2 diabetes, based on the National Diabetes Data Group criteria [2], of less than 5 years duration not taking any lipid lowering drugs, the only treatment being diet modification, were included. None had received insulin or sulphonylureas for at least 1 year before the study. The patients did not have nephrotic syndrome and their proteinuria was lower than 300 mg/day. Plasma cholesterol, HDL cholesterol and plasma triglycerides, were measured by enzymatic methods [3]. LDL cholesterol was calculated using the Friedewald's formula [4]. Lipoprotein A-I and B were quantified in total serum by nephelometry with Behring Institute reagents. Lp(a) was measured by an enzymeimmunoassay with a monoclonal antibody against Lp(a) and a polyclonal anti-Lp(a) antibody conjugated with peroxidase. The intra-assay coefficient of variation was 3.1% and the inter-assay coefficient of variation was 10%.  $\text{HbA}_{1c}$  was measured by a microcolumn chromatographic method with a reference range between 5.1–7.2%.

We found higher Lp(a) levels in diabetic females ( $12.40 \pm 11.34$  mg/100 ml) compared to diabetic males ( $5.35 \pm 7.6$  mg/100 ml;  $p < 0.02$ ) and control females ( $7.78 \pm 10.10$  mg/100 ml;  $p < 0.05$ ) (Table 1). We agree with Császár et al. [1] that Lp(a) levels are independent of metabolic control; we do not find differences related to  $\text{HbA}_{1c}$  when diabetic patients are compared to control subjects as proposed by other authors [5]. The remaining lipid parameters showed a similar pattern as those presented by Császár et al. The higher Lp(a) levels observed in female diabetic patients can be interpreted as an associated factor which could help to explain the increased cardiovascular risk observed in these patients [6].

We believe that risk factors for cardiovascular disease related to higher Lp(a) levels in diabetic patients, cannot be extrapolated to the general population. Because conflicting data about this lipoprotein are continuously emerging in the literature they should be interpreted with caution.

Yours sincerely,  
J. Vendrell, C. Gutiérrez, R. Pastor, and C. Richart

*Acknowledgement.* This work was supported by a grant of the PLANICID, number SAL-90-0426.

## References

- Császár A, Dieplinger H, Sandholzer C et al. (1993) Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus. *Diabetologia* 36: 47–51
- National Diabetes Data Group (1979) Classification diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 28: 1039–1057

**Table 1.** Lipid and lipoprotein plasma concentrations, laboratory data and clinical characteristics of the study subjects

	Control men <i>n</i> = 25	Type 2 diabetic men <i>n</i> = 15	Control women <i>n</i> = 35	Type 2 diabetic women <i>n</i> = 29
Age (years)	44.46 ± 6.64	50.78 ± 9.78	48.55 ± 10.08	54.22 ± 7.94
BMI (kg/m <sup>2</sup> )	26.65 ± 2.29	27.90 ± 5.07	26.13 ± 3.22	29.11 ± 5.69
Cholesterol (mmol/l)	5.22 ± 0.99	5.40 ± 0.81	6.00 ± 1.03	6.06 ± 1.13
LDL cholesterol (mmol/l)	3.28 ± 0.76	3.36 ± 0.74	3.89 ± 0.81	3.98 ± 0.98
HDL cholesterol (mmol/l)	1.31 ± 0.34	1.15 ± 0.27	1.41 ± 0.33	1.13 ± 0.32 <sup>a</sup>
Triglycerides (mmol/l)	1.55 ± 0.85	2.00 ± 0.89	1.54 ± 1.03	1.98 ± 1.12 <sup>a</sup>
Apo A-I (g/l)	1.58 ± 0.33	1.37 ± 0.21	1.78 ± 0.27	1.45 ± 0.28 <sup>b</sup>
Apo B (g/l)	1.30 ± 0.37	1.28 ± 0.32	1.32 ± 0.25	1.58 ± 0.38 <sup>a</sup>
Lp(a) (mg/100 ml)	10.05 ± 12.09	6.06 ± 7.87	7.54 ± 10.43	12.82 ± 11.29 <sup>a, c</sup>
HbA <sub>1c</sub> (%)	–	9.44 ± 2.66	–	9.03 ± 1.93

Results are expressed as mean ± SD.

<sup>a</sup> *p* < 0.05, <sup>b</sup> *p* < 0.001 compared to the control group, <sup>c</sup> *p* < 0.001 compared to the Type 2 diabetic men. Apo, Apolipoprotein; Lp(a), Lipoprotein (a)

- Röschlau P, Bernt E, Gruber W (1974) Enzymatic determination of total cholesterol in serum. *Z Klin Chem Klin Biochem* 12: 403–407
- Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18: 499–502
- Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P (1992) Lipoprotein (a) levels in diabetes mellitus. Relationship to metabolic control. *Ann Inter Med* 117: 42–47
- Walden CE, Knopp RH, Wahl PW et al. (1984) Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. *N Engl J Med* 311: 953–959

Dr. J. Vendrell  
Endocrinology Unit  
Internal Medicine Service  
Hospital de Tarragona Joan XXIII  
c/Dr. Mallafré Guasch, 4  
E-43007 Tarragona  
Spain

## Response from the authors

Dear Sir,  
Vendrell et al. [1] have studied Lp(a) in diabetic patients and claim that Lp(a) levels are higher in Type 2 (non-insulin-dependent) diabetic women (*n* = 29) than in Type 2 diabetic men (*n* = 15) and in control subjects (*n* = 35). Their subgroups are very small. Apo(a) types were not considered. The statistical method used is not stated.

Their data are inconsistent, with Type 2 diabetic men having the lowest Lp(a) level. In view of the large studies [2, 3] which do not find such a difference their result is almost certainly due to the small sample size and inappropriate statistical analysis.

Unfortunately small uncontrolled studies such as this are continuously emerging in the literature resulting in confusion concerning the relationship between Lp(a) and diabetes mellitus.

Yours sincerely,  
A. Császár, H. Dieplinger and G. Utermann

## References

- Vendrell J, Gutiérrez C, Pastor R, Richard C (1993) Plasma lipoprotein (a) concentration in diabetes mellitus (letter). *Diabetologia* 36: 881
- Császár A, Dieplinger H, Sandholzer C et al. (1993) Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus. *Diabetologia* 36: 47–51
- Haffner SM, Morales PA, Stern MP, Gruber MK (1992) Lp(a) concentrations in NIDDM. *Diabetes* 41: 1267–1272

Prof. G. Utermann  
Institute of Medical Biology  
and Human Genetics  
University Innsbruck  
Schöpfstrasse 41  
A-6020 Innsbruck  
Austria